VIOLIN: Vaccine Investigation and Online Information Network

Vaccine Detail

MART-1/gp100/Tyrosinase/MAGE-A3 Peptides-loaded Irradiated Allogeneic Plasmacytoid Dendritic Cells Vaccine

Vaccine Information

Vaccine Name: MART-1/gp100/Tyrosinase/MAGE-A3 Peptides-loaded Irradiated Allogeneic Plasmacytoid Dendritic Cells Vaccine
Target Pathogen: Cancer
Target Disease: Cancer
Vaccine Ontology ID: VO_0007505
Type: Recombinant vector vaccine
Status: Clinical trial
Host Species for Licensed Use: Human
Host Species as Laboratory Animal Model: Human
Antigen: PMEL, MAGEA3, MLANA
gp100 (PMEL) gene engineering:
- Type: Recombinant protein preparation
- Description: (Aspord et al., 2012)
- Detailed Gene Information: Click Here.
MAGEA3 gene engineering:
- Type: Recombinant protein preparation
- Description: (Aspord et al., 2012)
- Detailed Gene Information: Click Here.
MLANA gene engineering:
- Type: Recombinant protein preparation
- Description: (Aspord et al., 2012)
- Detailed Gene Information: Click Here.
Preparation: pDCs were loaded with tumor-derived HLA-A*0201-restricted peptides and the corresponding iTag HLA-A*0201 tetramers : MelA26–35 (ELAGIGILTV), GP100209–217 (IMDQVPFSV), tyrosinase369–377 (YMDGTMSQV), and MAGE-A3271–279 (FLWGPRALV) (Aspord et al., 2012).
Description: Irradiated allogeneic, HLA-A*0201 positive, plasmacytoid dendritic cells (pDCs) loaded with 4 melanoma peptides derived from the tumor associated antigens (TAAs) MelA/MART-1, gp100/pmel17, tyrosinase, and MAGE-A3, with potential immunostimulating and antineoplastic activities. Upon subcutaneous administration, the irradiated allogeneic pDCs may trigger functional multi-specific T cells from peripheral blood mononuclear cells and tumor-infiltrating lymphocytes, and activate the immune system to mount a cytotoxic T-lymphocyte response against HLA-A*0201 positive melanoma cancer cells expressing the TAAs MelA/MART-1, gp100/pmel17, tyrosinase, and MAGE-A3. These TAAs are upregulated in a variety of tumor cells. The pDCs are derived from a distinct subset of dendritic cells (DCs) with a plasma cell-like morphology and express a characteristic set of surface markers and may increase the anti-tumor immune responses. (NCIT_C107159).

Host Response

References

Aspord et al., 2012: Aspord C, Leccia MT, Salameire D, Laurin D, Chaperot L, Charles J, Plumas J. HLA-A(*)0201(+) plasmacytoid dendritic cells provide a cell-based immunotherapy for melanoma patients. The Journal of investigative dermatology. 2012; 132(10); 2395-2406. [PubMed: 22696054].

NCIT_C107159: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C107159]